Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Nurix Therapeutics Inc shares valued at $68,223 were sold by van Houte Hans on Feb 16 ’24. At $10.02 per share, van Houte Hans sold 6,812 shares. The insider’s holdings dropped to 68,333 shares worth approximately $1.18 million following the completion of this transaction.
Also, Hansen Gwenn sold 2,334 shares, netting a total of over 18,649 in proceeds. Following the sale of shares at $7.99 each, the insider now holds 36,402 shares.
Before that, Ring Christine had sold 1,760 shares from its account. In a trade valued at $14,063, the Chief Legal Officer traded Nurix Therapeutics Inc shares for $7.99 each. Upon closing the transaction, the insider’s holdings decreased to 1,760 shares, worth approximately $0.3 million.
Analysts at Barclays started covering the stock with ‘”an Overweight”‘ outlook in a report released in early March. As of February 28, 2023, Oppenheimer has initiated its “an Outperform” rating for NRIX. Earlier on October 11, 2022, Morgan Stanley initiated its rating. Their recommendation was “an Equal-weight” for NRIX stock.
Analyzing NRIX Stock Performance
During the last five days, there has been a surge of approximately 23.46%. Over the course of the year, Nurix Therapeutics Inc shares have jumped approximately 66.76%. Shares of the company reached a 52-week high of $18.12 on 04/11/24 and a 52-week low of $7.65 on 01/29/24. A 50-day SMA is recorded $12.29, while a 200-day SMA reached $9.19. Nevertheless, trading volume fell to 1.05 million shares from 1.91 million shares the previous day.
Support And Resistance Levels for Nurix Therapeutics Inc (NRIX)
According to the 24-hour chart, there is a support level at 16.34, which, if violated, would cause prices to drop to 15.47. In the upper region, resistance lies at 18.10. The next price resistance is at 18.99. RSI (Relative Strength Index) is 65.64 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 2.13, which suggests the price will increase in the coming days. Percent R is at 16.34%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
Is Nurix Therapeutics Inc subject to short interest?
Stocks of Nurix Therapeutics Inc saw a sharp steep in short interest on Mar 15, 2024 dropping by -0.86 million shares to 6.41 million. Data from Yahoo Finance shows that the short interest on Feb 15, 2024 was 7.27 million shares. A decline of -13.42% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.92 of the overall float, the days-to-cover ratio (short ratio) decline to 5.92.
